drugset / Trial / NCT02246764
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the ocular and systemic safety of Netarsudil (AR-13324) Ophthalmic Solution, 0.02% q.d. and b.i.d. for 12 months compared to the active comparator Timolol Maleate Ophthalmic Solution, 0.5%.
Timeline
- Start
- 2014-09
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Netarsudil | Small molecule | 0.02 % | Other |
| Comparator | Timolol | Other / unclassified | 0.5 % | Other |